BioCentury | Nov 10, 2017
Company News

Management tracks: Immunomedics, WuXi

Antibody company Immunomedics Inc. (NASDAQ:IMMU) appointed Michael Pehl president and CEO, effective Dec. 7, and Brendan Delaney chief commercial officer. Interim CEO Michael Garone will resume his role as CFO. Pehl was president of hematology...
BioCentury | Nov 4, 2013
Clinical News

Antara fenofibrate regulatory update

...2009, Lupin acquired U.S. rights to the product from Oscient Pharmaceuticals Corp. , which has been dissolved. Oscient...
BioCentury | Mar 12, 2012
Company News

Cornerstone Therapeutics, Merus Labs International sales and marketing update

...of Factive in the U.S. for 2011 were $6.3 million. Cornerstone had acquired Factive from Oscient Pharmaceuticals Corp....
BioCentury | May 9, 2011
Clinical News

Antara fenofibrate regulatory update

...regulatory action is needed. Fenofibrate products include lipid lowering drugs Antara fenofibrate from GlaxoSmithKline and Oscient...
...fenofibrate from SkyePharma. Cipher Pharmaceuticals Inc. (TSX:DND), Mississauga, Ontario LifeCycle Pharma A/S (CSE:LCP), Horsholm, Denmark Oscient Pharmaceuticals Corp....
BioCentury | Feb 8, 2010
Strategy

Out from Down Under

...products while at SmithKline Beecham plc (now GlaxoSmithKline plc ) and Genesoft Pharmaceuticals Inc. (now Oscient Pharmaceuticals Corp....
...Forest, Ill. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Leo Pharma A/S , Ballerup, Denmark Oscient Pharmaceuticals Corp....
BioCentury | Dec 21, 2009
Company News

Epix, Nanotherapeutics, Oscient deal

...Nanotherapeutics acquired Oscient's Ramoplanin for $500,000 in bankruptcy proceedings. The macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis...
...compounds, with the goal of out-licensing them at some point in the future. In July, Oscient...
...20 & July 27). Epix Pharmaceuticals Inc. (Pink:EPIX), Lexington, Mass. Nanotherapeutics Inc. , Alachua, Fla. Oscient Pharmaceuticals Corp....
BioCentury | Oct 5, 2009
Finance

Restructuring Watch

...campus located in Greenburgh, N.Y.; expects a "minor reduction in headcount" for redundant positions 7/13/09 Oscient Pharmaceuticals Corp....
BioCentury | Sep 7, 2009
Company News

Cornerstone Therapeutics, Oscient deal

...its previously announced acquisition of Factive gemifloxacin mesylate from Oscient. The deal will close "promptly." Oscient...
...for Chapter 11 in July (see BioCentury, July 20). Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C. Oscient Pharmaceuticals Corp....
BioCentury | Aug 20, 2009
Distillery Techniques

Technology: Drug platforms

...new ramoplanin analogs. Ramoplanin, a macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis from Pfizer Inc. and Oscient Pharmaceuticals Corp....
BioCentury | Aug 20, 2009
Distillery Techniques

Approach

...new ramoplanin analogs. Ramoplanin, a macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis from Pfizer Inc. and Oscient Pharmaceuticals Corp....
Items per page:
1 - 10 of 355
BioCentury | Nov 10, 2017
Company News

Management tracks: Immunomedics, WuXi

Antibody company Immunomedics Inc. (NASDAQ:IMMU) appointed Michael Pehl president and CEO, effective Dec. 7, and Brendan Delaney chief commercial officer. Interim CEO Michael Garone will resume his role as CFO. Pehl was president of hematology...
BioCentury | Nov 4, 2013
Clinical News

Antara fenofibrate regulatory update

...2009, Lupin acquired U.S. rights to the product from Oscient Pharmaceuticals Corp. , which has been dissolved. Oscient...
BioCentury | Mar 12, 2012
Company News

Cornerstone Therapeutics, Merus Labs International sales and marketing update

...of Factive in the U.S. for 2011 were $6.3 million. Cornerstone had acquired Factive from Oscient Pharmaceuticals Corp....
BioCentury | May 9, 2011
Clinical News

Antara fenofibrate regulatory update

...regulatory action is needed. Fenofibrate products include lipid lowering drugs Antara fenofibrate from GlaxoSmithKline and Oscient...
...fenofibrate from SkyePharma. Cipher Pharmaceuticals Inc. (TSX:DND), Mississauga, Ontario LifeCycle Pharma A/S (CSE:LCP), Horsholm, Denmark Oscient Pharmaceuticals Corp....
BioCentury | Feb 8, 2010
Strategy

Out from Down Under

...products while at SmithKline Beecham plc (now GlaxoSmithKline plc ) and Genesoft Pharmaceuticals Inc. (now Oscient Pharmaceuticals Corp....
...Forest, Ill. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Leo Pharma A/S , Ballerup, Denmark Oscient Pharmaceuticals Corp....
BioCentury | Dec 21, 2009
Company News

Epix, Nanotherapeutics, Oscient deal

...Nanotherapeutics acquired Oscient's Ramoplanin for $500,000 in bankruptcy proceedings. The macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis...
...compounds, with the goal of out-licensing them at some point in the future. In July, Oscient...
...20 & July 27). Epix Pharmaceuticals Inc. (Pink:EPIX), Lexington, Mass. Nanotherapeutics Inc. , Alachua, Fla. Oscient Pharmaceuticals Corp....
BioCentury | Oct 5, 2009
Finance

Restructuring Watch

...campus located in Greenburgh, N.Y.; expects a "minor reduction in headcount" for redundant positions 7/13/09 Oscient Pharmaceuticals Corp....
BioCentury | Sep 7, 2009
Company News

Cornerstone Therapeutics, Oscient deal

...its previously announced acquisition of Factive gemifloxacin mesylate from Oscient. The deal will close "promptly." Oscient...
...for Chapter 11 in July (see BioCentury, July 20). Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C. Oscient Pharmaceuticals Corp....
BioCentury | Aug 20, 2009
Distillery Techniques

Technology: Drug platforms

...new ramoplanin analogs. Ramoplanin, a macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis from Pfizer Inc. and Oscient Pharmaceuticals Corp....
BioCentury | Aug 20, 2009
Distillery Techniques

Approach

...new ramoplanin analogs. Ramoplanin, a macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis from Pfizer Inc. and Oscient Pharmaceuticals Corp....
Items per page:
1 - 10 of 355